## Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Academy of Kidney Cancer Investigators – Early-Career Scholar Award | Must be within 4 years of their last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.) or equivalent as of the full application submission deadline. **A letter attesting to eligibility is required.** | • Supports the addition of new Early-Career Scholars to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.  
• Early-Career Scholars whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.  
• A Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding is required.  
• The Designated Mentor is not required to be at the same institution as the Early-Career Scholar.  
• **Preliminary data are required.**  
• **Clinical trials are not allowed.** | • Maximum funding of **$725,000** for direct costs (plus indirect costs).  
• Maximum period of performance is **4 years.**  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-Application (Letter of Intent): September 29, 2022 5:00 p.m. Eastern time  
Application: October 20, 2022 11:59 p.m. Eastern time |
| Nurse-Initiated Research Award | Must have a Registered Nurse license and/or a Master’s or Doctoral degree in nursing. | • Supports nursing research pertaining to kidney cancer patient care.  
• **Clinical trials are not allowed; correlative studies to clinical trials are allowed.**  
• **Qualified Collaboration Option:** Leveraging of existing infrastructure of a federally funded partnership/consortium is encouraged. | • Maximum funding of **$300,000** for direct costs (plus indirect costs).  
• Maximum period of performance is **2 years.**  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-Application (Letter of Intent): September 29, 2022 5:00 p.m. Eastern time  
Application: October 20, 2022 11:59 p.m. Eastern time |
## Fiscal Year 2022 Department of Defense Kidney Cancer Research Program (KCRP)
### Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Clinical Trial Award | Independent investigators at all levels. | • Supports projects ranging from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.  
• Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.  
• Investigational New Drug (IND) or Investigational Device Exemption (IDE) application, if applicable, must be submitted to the U.S. Department of Food and Drug Administration (FDA) by the time of application submission.  
• Documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study must be provided.  
• Clinical trials are expected to begin no later than 12 months after the award date, or 18 months after the award date for FDA-regulated studies.  
• **Qualified Collaboration Option:** Leveraging of existing infrastructure of a federally funded partnership/consortium is encouraged. | • Maximum funding of **$1,500,000** for direct costs (plus indirect costs).  
• Maximum period of performance is 4 years.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-Application (Letter of Intent):  
September 29, 2022  
5:00 p.m. Eastern Time  
Application:  
October 20, 2022  
11:59 p.m. Eastern Time |
| Grants.gov Funding Opportunity Number: W81XWH-22-KCRP-CTA | | | | |
## Fiscal Year 2022 Department of Defense Kidney Cancer Research Program (KCRP)
### Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Concept Award Go to:          | All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible. | • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.  
• Emphasis on innovation.  
• Preliminary data are not allowed.  
• Clinical trials are not allowed.  
• Blinded review. | • Maximum of $100,000 for direct costs (plus indirect costs).  
• Maximum period of performance is 1 year.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-Application (Letter of Intent):  
June 23, 2022  
5:00 p.m. Eastern time  
Application:  
July 14, 2022  
11:59 p.m. Eastern time |

Grants.gov Funding Opportunity Number: W81XWH-22-KCRP-CA
# Fiscal Year 2022 Department of Defense Kidney Cancer Research Program (KCRP)
## Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Idea Development Award                    | Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or Early-Career Investigators: Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission. | • Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.  
  • Innovation and Impact are the most important review criteria.  
  • Different funding options, based on the scope of the proposed research, are available with compelling justification.  
  • **Preliminary data are required.**  
  • **Clinical trials are not allowed.** | • Maximum funding of $675,000 in direct costs (plus indirect costs).  
  • Period of performance not to exceed 3 years.  
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-Application (Preproposal): June 2, 2022  
5:00 p.m. Eastern time  
Invitation to Submit an Application: July 14, 2022  
Application: October 6, 2022  
11:59 p.m. ET |

**Grants.gov Funding Opportunity Number:**  
**W81XWH-22-KCRP-IDA**
### Fiscal Year 2022 Department of Defense Kidney Cancer Research Program (KCRP) Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Postdoctoral and Clinical Fellowship Award</strong></td>
<td>Must have completed requirements for a Ph.D. and/or M.D.</td>
<td>- Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers.</td>
<td>- Maximum funding of $195,000 for direct costs (plus indirect costs).</td>
<td>Pre-Application (Letter of Intent): June 23, 2022 5:00 p.m. Eastern time</td>
</tr>
<tr>
<td>Go to:</td>
<td>Must be in the laboratory or clinical setting where proposed research will be performed.</td>
<td>- A designated mentor who is an experienced kidney cancer researcher is required.</td>
<td>- Maximum period of performance is 3 years.</td>
<td>Application: July 14, 2022 11:59 p.m. Eastern time</td>
</tr>
<tr>
<td>Grants.gov Funding Opportunity Number: W81XWH-22-KCRP-PCFA</td>
<td>Must have no more than 4 years of postdoctoral and/or mentored clinical research experience.</td>
<td>- Clinical trials are not allowed.</td>
<td>Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</td>
<td></td>
</tr>
</tbody>
</table>

**Investigators in non-postdoctoral and/or clinical fellow positions are not eligible.**

| **Translational Research Partnership Award**         | The Initiating Principal Investigator (PI) must be at or above the level of Assistant Professor or equivalent. | Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications. | Maximum funding of $750,000 for direct costs (plus indirect costs).                                                                  | Pre-Application (Preproposal): June 2, 2022 5:00 p.m. Eastern time                   |
| Go to:                                               | The Partnering PI must be at or above the level of Assistant Professor or equivalent.       | Supports translational correlative studies.                                           | Maximum period of performance is 3 years.                                                                                             | Invitation to Submit an Application: July 14, 2022                                  |
| Grants.gov Funding Opportunity Number: W81XWH-22-KCRP-TRPA | Postdoctoral fellows are not eligible to be Partnering PIs. | Preliminary data are required.                                                      | Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.                                          | Application: October 6, 2022 11:59 p.m. ET                                       |